Elanco Animal Health (ELAN) Cash & Equivalents (2017 - 2026)

Elanco Animal Health has disclosed Cash & Equivalents across 10 years of filings, most recently posting $428.0 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $428.0 million, down 12.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $428.0 million (down 12.11% YoY), and the FY2025 annual result was $545.0 million, up 16.45% from the prior year.
• Cash & Equivalents came in at $428.0 million for Q1 2026 at Elanco Animal Health, down from $545.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $545.0 million in Q4 2025 to a low of $318.0 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $428.0 million (2026), against an average of $428.4 million.
• Across the five-year window, Cash & Equivalents slumped 45.92% in 2022 and surged 41.16% in 2025, its largest moves.
• Elanco Animal Health's Cash & Equivalents stood at $345.0 million in 2022, then rose by 2.03% to $352.0 million in 2023, then soared by 32.95% to $468.0 million in 2024, then grew by 16.45% to $545.0 million in 2025, then fell by 21.47% to $428.0 million in 2026.
• The last three Cash & Equivalents figures came in at $428.0 million (Q1 2026), $545.0 million (Q4 2025), and $505.0 million (Q3 2025), per Business Quant data.